Therapy Directory

Antibody-drug conjugates clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Antibody-drug conjugates as a study intervention. Browse Antibody-drug conjugates recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 1:06 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

503

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Epithelial Ovarian Cancer
Interventions: Torvutatug samrotecan, Bevacizumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 950 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 4
States / cities: Tampa, Florida • Baltimore, Maryland • Billings, Montana + 1 more

Conditions: Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
Interventions: AZD0901, 5-Fluorouracil, Leucovorin, l-leucovorin, Irinotecan, Nanoliposomal Irinotecan, Gemcitabine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: Orange, California • Palo Alto, California • Santa Rosa, California + 4 more

Conditions: Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Renal Cell Carcinoma
Interventions: FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Palo Alto, California • Chicago, Illinois • Omaha, Nebraska + 3 more

Conditions: NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC, Colo-rectal Cancer, Head and Neck Cancer, Esophageal Squamous Cell Carcinoma (ESCC)
Interventions: ALX2004; Drug
Lead sponsor: ALX Oncology Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 12
States / cities: La Jolla, California • Santa Monica, California • Tampa, Florida + 9 more

Conditions: Colon Cancer, Pancreatic Cancer, Lung Cancer (NSCLC), Advanced Cancer, Advanced Solid Tumors
Interventions: PHN-012; Drug
Lead sponsor: Pheon Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 11
States / cities: Los Angeles, California • San Diego, California • Washington D.C., District of Columbia + 8 more

Conditions: Breast Cancer
Interventions: Trastuzumab deruxtecan (DS-8201a), Capecitabine, Eribulin, Gemcitabine, Paclitaxel, Nab-paclitaxel; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 557 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 38
States / cities: Chandler, Arizona • Gilbert, Arizona • Goodyear, Arizona + 31 more

Conditions: Advanced Solid Tumor
Interventions: BG-C0979, Tislelizumab; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Boston, Massachusetts • St Louis, Missouri • Hackensack, New Jersey + 1 more

Conditions: Solid Tumor
Interventions: BHV-1510, Cemiplimab; Drug
Lead sponsor: Biohaven Therapeutics Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 17
States / cities: Duarte, California • La Jolla, California • Palo Alto, California + 14 more

Conditions: Locally Advanced or Metastatic Urothelial Carcinoma
Interventions: Avelumab, Sacituzumab Govitecan (SG), M6223, NKTR-255, JB100; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 8
States / cities: Coeur d'Alene, Idaho • Kansas City, Kansas • Baltimore, Maryland + 4 more

Conditions: Solid Tumors, Advanced Solid Tumor
Interventions: BG-C0902; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Houston, Texas • San Antonio, Texas • Fairfax, Virginia

Conditions: Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
Interventions: IKS014; Drug
Lead sponsor: Iksuda Therapeutics Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: Newport Beach, California • Boston, Massachusetts • Nashville, Tennessee + 1 more

Conditions: Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
Interventions: AZD9592, Osimertinib, 5-Fluorouracil (5-FU), Leucovorin, Bevacizumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 15
States / cities: Duarte, California • North Haven, Connecticut • Washington D.C., District of Columbia + 9 more

About this Antibody-drug conjugates clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Antibody-drug conjugates as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Antibody-drug conjugates.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Antibody-drug conjugates clinical trials

Filter and sort this therapy

Live official records

Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

A Study of PHN-012 in Patients With Advanced Solid Tumors

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

IKS014 in Advanced Solid Tumors That Express HER2

First in Human Study of AZD9592 in Solid Tumors

About this Antibody-drug conjugates clinical trials directory page